3 not yet recruiting, 2 recruiting. 2 Not applicable, 2 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Tirzepatide: new trials by email Literature Review of Tirzepatide trials Research Report on Tirzepatide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation Discontinuation and Reinitiation of Tirzepatide - Drug Discontinuation, Substance Use Disorders | Not applicable | Recruiting | The University of Texas at Dallas | 40 | 2026-10-01 | 2026-09-02 |
| Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer Dual GIP/GLP-1 receptor agonist - Tirzepatide, Frozen Embryo Transfer | Not applicable | Not yet recruiting | RenJi Hospital | 1510 | 2026-09-01 | 2026-09-10 |
| Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF Tirzepatide, Structured Lifestyle Intervention - Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 4 | Not yet recruiting | Yunlong Wang | 602 | 2026-08-01 | 2026-06-05 |
| Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity Tirzepatide, Placebo - Heart Failure and Reduced Ejection Fraction, Obesity & Overweight | Phase 3 | Not yet recruiting | Shahid Beheshti University of Medical Sciences | 60 | 2026-07-18 | 2026-08-03 |
| Tirzepatide (Spartina) in Obese Kidney Transplant Recipients Tirzepatide - Tirzepatide | Phase 4 | Recruiting | Shahid Beheshti University of Medical Sciences | 30 | 2026-01-01 | 2026-02-20 |
Obesity (3) · Atrial Fibrillation (1) · Heart Failure, Systolic (1) · Overweight (1) · Substance-Related Disorders (1) · Weight Loss (1)
Body Weight (3) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3) · Overnutrition (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Cardiovascular Diseases (2) · Heart Diseases (2) · Overweight (2) · Arrhythmias, Cardiac (1) · Body Weight Changes (1) · Chemically-Induced Disorders (1) · Heart Failure (1) · Mental Disorders (1) · Pathologic Processes (1)
Tirzepatide (4)
Shahid Beheshti University of Medical Sciences (2) · RenJi Hospital (1) · The University of Texas at Dallas (1) · Yunlong Wang (1)
China (2) · Iran (1) · United States (1)
Francesca Filbey, Doctor of Philosophy (1) · Nooshin Dalili (1) · Yunlong Wang, PHD (1)